SARS-CoV-2 Research, Vaccine and Therapeutic Development
In addition to the need for fast development of assays to detect SARS-CoV-2 and identify exposed individuals, the COVID-19 crises has led to massive worldwide efforts to develop drug treatments and vaccines effective against SARS-CoV-2. A more comprehensive understanding of the biology of the SARS-CoV-2 virus is also needed. We support scientists working to develop vaccines and to answer questions about viral pathology and treatment including:
- How does the virus enter human cells?
- How does the virus make people sick?
- What treatments can be used to alleviate symptoms?
- How can immunity to the virus be gained?
We offer collaborative support and a broad portfolio of reagents that are used in research labs studying coronaviruses and other emerging viral diseases.
Monitor Immune Response
A key question asked by viral researchers is how a host’s immune system responds to the viral infection, including both adaptive and innate immunity. The innate immune response involves activation of inflammasomes and cytokine release. While this cytokine release is therapeutic, a “cytokine storm” can be an adverse side effect in patients that must be managed with additional therapeutics designed to block the efficacy of the released cytokines such as IL-6 and IL-15.
In addition to the innate immune response, humoral and cellular responses play key roles in host response. These questions can be answered with reporter bioassays as well as assays to detect the activity of caspase-1 and levels of cytokines in cell-based research applications.
Application Note: Screening IL-6 Pathway Small and Large Molecule Inhibitors with Lumit™ pSTAT3 (Tyr705) Immunoassay
Webinar: ADCC Bioassays in Influenza Vaccine Development
Poster: Bioluminescent Cell-based Assay Platforms for Quantitative Measurement of ADCC/ADCP Activities for SARS-CoV-2 Antibodies
RNA Production for Vaccine Research and Development
Transcribed RNA is required for vaccine production, viral standards, and basic viral research. For in vivo and in vitro studies, RiboMAX® RNA Production System generates a large quantity of high-quality RNA or mRNA from a DNA template without the need for mammalian cells or cell components. These in-vitro transcribed viral RNA or mRNA transcripts, typically encoding a disease-specific antigen such as the spike protein of a coronavirus, may be used as inoculation material for viral infection studies. If the transcribed mRNA is to be used as a therapeutic, the mRNA encoding a desirable protein can be packaged as necessary for delivery to the tissue of interest.
Generation of Coronavirus RNA
Eriksson K.K., et al. (2008) Generation of Recombinant Coronaviruses Using Vaccinia Virus as the Cloning Vector and Stable Cell Lines Containing Coronaviral Replicon RNAs. In: Cavanagh D. (eds) SARS- and Other Coronaviruses. Methods in Molecular Biology (Methods and Protocols), vol 454. Humana Press, Totowa, NJ.
Ding X., et al. (2020) All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-Cov-2 and HIV virus. BioRxiv accessed April 13 2020. doi.org/10.1101/2020.03.19.998724
Standard RNA production with RiboMAX
Xu, L. et al. (2009) Evaluation of Sensitivities and Specificities of SARS-CoV Detection by Real-Time Quantitative Reverse Transcription-PCR Assays. Virologica Sinica, 24 (3), 187-193. DOI 10.1007/s12250-009-3021-8
The bioluminescence technology used in Promega reagents for viral research make the assays highly sensitive and simple to use. GloMax® plate-readers come with pre-loaded protocols that make reading and interpreting results from Promega luminescence assays even simpler.